Sign In
Buy IMMP
$0.407
-0.0093 (-2.24%)
At Close: Jun 03, 2026
Here's What We Think About Immutep Limited's (ASX:IMM) CEO Pay
02:53am, Tuesday, 11'th Feb 2020
Marc Voigt has been the CEO of Immutep Limited (ASX:IMM) since 2014. This report will, first, examine the CEO...
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
01:00pm, Tuesday, 04'th Feb 2020
SYDNEY, Australia, Feb. 04, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for.
Immutep Activities Report
01:00pm, Wednesday, 29'th Jan 2020
First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in.
Analysts Offer Insights on Healthcare Companies: Immutep (NASDAQ: IMMP) and Sintx Technologies (NASDAQ: SINT)
12:35pm, Saturday, 11'th Jan 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immutep (IMMP – Research Report)
